You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
23andMe had sued Ancestry.com for, among other things, infringing a patent related to a method for determining the degree to which two people in a database are related.
In a court filing, lawyers say Elizabeth Holmes, the former CEO of Theranos, hasn't paid them in a year, the Mercury News reports.
Personal Genomics alleged that PacBio tried to sublicense the patent-in-suit in the years prior to its launch of the Sequel sequencing platform.
CareDx claims that Eurofins Viracor infringes on its patent related to noninvasive monitoring of organ transplant rejection through cell-free DNA analysis.
Retraction Watch reports on the latest goings-on with Carlo Croce's lawsuit against Ohio State University.
The lawsuit, filed on the eve of 10x's IPO, alleges that 10x's new Next GEM microfluidic chips infringe a patent exclusively licensed to Bio-Rad.
The UK-based sequencing technology firm continues to seek invalidation of PacBio's patents, despite unsuccessful earlier efforts.
The South San Francisco, California cellular analysis firm alleges IonPath has infringed two patents and has been intereferening in its contracts.
The victory for the sequencing giant is just the latest in a string of favorable decisions before the US Patent Trial and Appeals Board.
In response to BD's patent suit, 10x alleged BD's single-cell products infringe its own patents. 10x also asked the judge to dismiss BD's lawsuit.
Nature News reports the US National Institutes of Health is investing in studies of the long-term effects of COVID-19.
The National Health Service is to offer Novartis's Zolgensma for spinal muscular atrophy later this year, according to the Guardian.
Taiwan is to launch a pilot program offering genetic testing to cancer patients, the Taipei Times reports.
In PLOS this week: loci linked to protection against tuberculosis, identification of loci associated with increased risk of squamous cell carcinoma of the aerodigestive tract, and more.